Ocuphire (OCUP) PT Raised to $22 at Cantor Fitzgerald, Following Clinical Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts OCUP Hot Sheet
Price: $1.17 --0%
Rating Summary:
6 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 9 | Down: 14 | New: 1
Rating Summary:
6 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 9 | Down: 14 | New: 1
Join SI Premium – FREE
Cantor Fitzgerald analyst Kristen Kluska raised the price target on Ocuphire (NASDAQ: OCUP) to $22.00 (from $20.00) while maintaining a Overweight rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Progyny (PGNY) PT Raised to $38 at Citizens After Guidance Raise
- Smith & Nephew PLC. (SN:LN) (SNN) PT Raised to GBP12.10 at UBS
- Novo Nordisk (NOVOB:DC) (NVO) PT Lowered to DKK312 at UBS
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Cantor FitzgeraldSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
